About GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. The company is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early, using next-generation sequencing, population-scale clinical studies, and computer and data science to deepen the scientific understanding of cancer biology.
GRAIL’s first product is the Galleri multi-cancer early detection test. According to company materials, Galleri detects a signal shared by more than 50 types of cancer through a routine blood draw, and when a signal is detected the test can predict the cancer signal origin to help guide diagnostic evaluation. GRAIL describes Galleri as an addition to guideline-recommended screening for adults with elevated risk for cancer rather than a replacement for existing screenings.
GRAIL’s technology is built on the science of cell-free DNA and targeted methylation analysis. In submissions to clinical guideline panels, the company has described its multi-cancer early detection approach as identifying a methylation-based cancer signal from circulating cell-free DNA in peripheral blood, with the goal of detecting aggressive cancers while maintaining a low false positive rate.
The company’s clinical evidence program includes large-scale studies. The Circulating Cell-Free Genome Atlas (CCGA) study was described by GRAIL as the largest prospective clinical genomics program, with over 15,000 participants, used to discover, develop, and validate its methylation-based blood test for multi-cancer early detection. The PATHFINDER study was a prospective, interventional study examining use of Galleri in clinical practice among adults aged 50 and older with and without additional cancer risk factors.
GRAIL reports that its clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The company has stated that the Galleri test has not been approved by the Food and Drug Administration.
The company has built a multi-disciplinary organization of scientists, engineers, and physicians working to overcome one of medicine’s greatest challenges. GRAIL is supported by leading global investors and pharmaceutical, technology, and healthcare companies, and works with stakeholders to adopt innovative, safe, and effective technologies intended to transform cancer care.
GRAIL is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom. It recruits across research and development, laboratory operations, regulatory affairs, quality, commercial, and corporate functions. Its open roles span sites including Menlo Park, Sunnyvale, and Durham, North Carolina, alongside remote and field-based commercial positions.
Further information about the company and its Galleri test is available through its official website.
